Pfizer, Astellas first-line bladder cancer therapy accepted for review in China [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
conjugate it co-develops with Pfizer ( NYSE: PFE ), as a first-line option for certain patients with bladder cancer. On Wednesday, China's Center for Drug Evaluation accepted a supplemental biologics license application ((sBLA)) for Padcev in combination with Merck's ( MRK ) PD-1 inhibitor Keytruda for treatment naïve adults with locally advanced or metastatic urothelial cancer, the company said. If approved, the Padcev/Keytruda combo will offer a new treatment regimen for the patient group that has to rely on chemotherapy as the current standard of care. Padcev, also known as enfortumab vedotin, is also under regulatory review in China as a late-line treatment for patients with urothelial cancer who have previously received a PD-1/L1 inhibitor and chemotherapy. Pfizer ( PFE ) added Padcev to its portfolio in December with its ~$43B acquisition of ADC drug developer Seagen. Recommended For You More Trending News Recommended For You More Trending News Related Stocks
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Gen AI Revolution Is Reshaping The Future Of Traditional Consulting [Forbes]Forbes
- FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia [Yahoo! Finance]Yahoo! Finance
- Rep. David Trone emphasizing public service, systemic reform in Maryland senate race [CBS News]CBS News
- FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder [MSNBC.com]MSNBC.com
- What Factors Will Drive Pfizer's Q1 Performance? [Forbes]Forbes
PFE
Earnings
- 1/30/24 - Beat
PFE
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- PFE's page on the SEC website